Pharmafile Logo
Pharmafocus logo
Advanced Search

Kyprolis

Showing 15 posts of 15 posts found.

amgen_hq

NICE turns down Amgen’s multiple myeloma drug

November 9, 2016
Research and Development, Sales and Marketing Amgen, Kyprolis, NICE

Amgen has seen its drug Kyprolis (carfilzomib) rejected by NICE for its routine use in the treatment of multiple myeloma …

News
ema_inside

EMA opens clinical trial data to public

October 25, 2016
Manufacturing and Production Amgen, AstraZeneca, EMA, EU, Kyprolis, clinical reports, clinical trials

The European Medicine Agency has begun to release to the public data on clinical trial via their own website. The …

News
amgen_hq

Amgen’s Kyprolis disappoints in Phase III trial

September 27, 2016
Manufacturing and Production, Research and Development Amgen, Kyprolis, phase III

Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …

News
amgen_hq

Amgen says its blood cancer drug gets European backing for extended indication

July 4, 2016
Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial

Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …

News
amgen_flag

Amgen showcases positive Phase III multiple myeloma drug at ASCO

June 7, 2016
Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma

Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …

News
amgen_flag

Amgen’s Kyprolis now available to UK multiple myeloma patients

February 12, 2016
Medical Communications, Sales and Marketing Amgen, Kyprolis, multiple myeloma

Amgen has announced the UK launch of Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of …

News
Amgen image

FDA approves new Kyprolis combo for multiple myeloma

January 22, 2016
Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma

Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …

News
kyprolis_amgen

Amgen’s Kyprolis doubles Velcade benefit in head-to-head study

December 5, 2015
Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma

Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …

News
Amgen image

Amgen’s Kyprolis gets accelerated FDA review for expanded labelling

September 21, 2015
Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma

The FDA has accepted for priority review Amgen’s supplemental new drug application for Kyprolis (carfilzomib) for patients with relapsed multiple …

News
Amgen image

Amgen files high earnings for Q1

April 22, 2015
Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis

Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …

News
Onyx pharma image

Treatment shifts away from chemotherapy for multiple myeloma

December 10, 2014
Research and Development, Sales and Marketing Kyprolis, carfilzomib, chemotherapy, myeloma, onyx pharmaceuticals

Results from a Phase III study of a new multiple myeloma offering have found promising results for a treatment that …

News
Amgen image

Speedy FDA nod for Amgen leukaemia drug

December 5, 2014
Research and Development, Sales and Marketing B-cell lymphoblasts, FDA, Kyprolis, blinatumomab, blincyto, leukaemia

The FDA has approved Amgen’s Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia (B-cell ALL). …

News
amgen image

Amgen cancer drug fails key test

August 14, 2014
Sales and Marketing Amgen, Cancer, Kyprolis, myeloma

Amgen’s new rare cancer drug has failed in a late-stage trial just a year after the US biotech spent $10.4 …

News
amgen

Amgen buys Onyx for $10.4 billion

August 27, 2013
Research and Development, Sales and Marketing Amgen, Kyprolis, Onyx

News
Velcade image

Speedy approval for Onyx’ multiple myeloma drug

July 24, 2012
Research and Development, Sales and Marketing FDA, Janssen, Kyprolis, Onyx, Takeda, Velcade

Onyx’ Kyprolis has gained an accelerated approval by the FDA to treat patients with late-stage multiple myeloma.  Kyprolis (carfilzomib), a …

News

Latest content

FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis

September 22, 2023

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

September 22, 2023

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023